---
company: CV Sciences, Inc.
ticker: CVSI
form: 8-K
filed: 2026-08-13
accession: 0001193125-26-349136
source: https://www.sec.gov/Archives/edgar/data/1510964/000119312526349136/
---

# CV Sciences (CVSI) earnings release, August 13, 2026

CV Sciences, Inc. (CVSI) · Form 8-K, Item 2.02 · Filed 2026-08-13 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1510964/000119312526349136/)

CV Sciences, Inc. Reports Second Quarter-End 2026 Financial Results

San Diego, CA - August 13, 2026 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended June 30, 2026.

Second Quarter 2026 and Recent Financial, Operating and Regulatory Highlights

• Generated revenue of $3.0 million for the second quarter 2026 compared to $3.6 million for the second quarter 2025 and compared to $3.2 million for the first quarter 2026;

• Recognized gross margin of 48.6% for the second quarter 2026 compared to 50.9% for the second quarter 2025 and compared to 48.9% for the first quarter 2026;

• Cash balance of $0.3 million at quarter and year end;

• Reduced operating expenses by 11.3% to $1.7 million for the second quarter 2026 compared to $2.0 million for the second quarter 2025, and by 6.9% from $1.9 million in the first quarter 2026;

• Recognized an adjusted EBITDA loss of $0.1 million for the second quarter 2026 compared to positive adjusted EBITDA of $0.1 million for second quarter 2025 and compared to an adjusted EBITDA loss of $0.1 million for the first quarter 2026;

• Expanded the +PlusHLTH™ portfolio with personalized wellness solutions for healthy aging;

• Launched PlusHLTH.com, a new dedicated e-commerce platform strengthens the Company's strategy to build a leading science-backed health and wellness portfolio; and

• U.S. Senate voted 61-32 to approve Continuing Resolution H.R. 6500, which delays the implementation of restrictive provisions for hemp-derived cannabinoid products, allowing valuable time to develop a longer-term solution and sensible regulatory framework for hemp-derived products.

"Our second quarter results reflect continued disciplined execution despite a challenging regulatory and consumer environment. While revenue remained under pressure, we maintained healthy gross margins, further reduced operating expenses, and continued to strengthen the financial foundation of the business. We believe these actions position us to improve profitability and generate positive cash flow as market conditions normalize," stated Joseph Dowling, Chief Executive Officer of CV Sciences. "During the quarter, we also expanded our +PlusHLTH™ portfolio with personalized wellness solutions designed to support healthy aging, further advancing our strategy to diversify beyond cannabinoids into broader science-based wellness categories. Looking ahead, we remain focused on disciplined capital allocation, operational excellence, and selectively pursuing strategic opportunities that strengthen our brands and create long-term shareholder value."

Operating Results - Second Quarter 2026 Compared to Second Quarter 2025

Sales for the second quarter 2026 were $3.0 million, a decrease of 17.5% from $3.6 million in the second quarter 2025. The decline is driven by lower sales volume due to restrictive regulations at the federal level and in certain states. The total number of units sold during the second quarter 2026 decreased by 14.9% compared to the second quarter of 2025. We also realized some minor decreases in average sales prices. In addition, 44% of our net revenue for the second quarter 2026 was from new products launched since January 1, 2023. During this time period, we launched 52 new products.

We generated an operating loss of $0.3 million in the second quarter 2026, compared to an operating loss of f $0.1 million in the second quarter 2025. The change is mostly due to lower sales and associated gross profit, partially offset by reduced operating expenses. We had negative adjusted EBITDA of $0.1 million for the second quarter 2026 compared to positive adjusted EBITDA of $0.1 million in the second quarter 2025.

Conference Call and Webcast

The Company will host a conference call and webcast to discuss these results today at 4:30 pm EDT/1:30 pm PDT. The webcast of the conference call will be available on the Investor Relations section of the Company's website at https://ir.cvsciences.com/news-events or directly at https://viavid.webcasts.com/starthere.jsp?ei=1769578&tp_key=ae0ce79bc9. Investors interested in participating in the live call can also dial (877) 407-0784 from the U.S. or international callers can dial (201) 689-8560. A telephone replay will be available approximately three hours after the call concludes, and will be available through Thursday, August 20, 2026, by dialing (844) 512-2921 from the U.S. or (412) 317-6671 from international locations, and entering confirmation code 13761707.

About CV Sciences, Inc.

CV Sciences, Inc. (OTCQB:CVSI) is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company's hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from B2B to B2C. The Company's +PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are the top-selling hemp-extract brand in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. With a commitment to science, +PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. +PlusCBD™ was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. The Company also produces non-cannabinoid supplements under its +PlusHLTH™ brand, with targeted formulations to optimize health, improve performance, and increase vitality. Our Cultured Foods™ brand provides a variety of 100% plant-based food products that are distributed primarily in the EU and other select markets. Cultured Foods™ caters to individuals seeking vegan, gluten-free, or flexitarian options for a wholesome and satisfying culinary experience. In addition, the Company owns Elevated Softgels, a leading manufacturer of encapsulated softgels and tinctures for the supplement and nutrition industry. CV Sciences, Inc. has primary offices and facilities in San Diego, California, Grand Junction, Colorado, and Warsaw, Poland. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.

Forward Looking Statements

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risk and uncertainties. CV Sciences does not undertake any obligation to publicly update any forward-looking statements, except as required by applicable law. As a result, investors should not place undue reliance on such forward-looking statements.

Contact Information ir@cvsciences.com

## Financial statements

### Income Statement (Three Months Ended June 30, — (in thousands, except per share data))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Product sales, net | 2,985 | 3,620 | 6,180 | 7,226 |
| Cost of goods sold | 1,535 | 1,776 | 3,168 | 3,724 |
| Gross profit | 1,450 | 1,844 | 3,012 | 3,502 |
| Operating expenses: | Research and development | 18 | 50 | 36 | 80 |
| Operating expenses: | Selling, general and administrative | 1,733 | 1,925 | 3,595 | 4,064 |
| Operating expenses: | Benefit from reversal of accrued payroll taxes |  |  |  | -522 |
| Operating expenses: | Total operating expenses | 1,751 | 1,975 | 3,631 | 3,622 |
| Operating expenses: | Operating loss | -301 | -131 | -619 | -120 |
| Other expense (income): | Gain on extinguishment of debt |  |  | -20 | -38 |
| Other expense (income): | Loss on debt conversion | 104 |  | 249 |  |
| Other expense (income): | Change in fair value of convertible notes | 364 |  | 471 |  |
| Other expense (income): | Interest expense, net | 1 | 130 | 94 | 281 |
| Other expense (income): | Total other expense | 469 | 130 | 794 | 243 |
| Other expense (income): | Loss before income taxes | -770 | -261 | -1,413 | -363 |
| Other expense (income): | Income tax expense | 5 |  | 5 | 7 |
| Other expense (income): | Net loss | -775 | -261 | -1,418 | -370 |
| Other expense (income): | Weighted average common shares outstanding, basic and diluted | 205,086 | 184,264 | 198,943 | 184,264 |
| Other expense (income): | Net loss per common share, basic and diluted | 0 | 0 | -0.01 | 0 |

### Income Statement (Three Months Ended June 30, (in thousands, except per share data))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Net loss - GAAP | -775 | -261 | -1,418 | -370 |
| Stock-based compensation (1) | 148 | 132 | 296 | 250 |
| Loss on debt conversions (2) | 104 |  | 249 |  |
| Change in fair value of convertible notes (3) | 364 |  | 471 |  |
| Gain on debt extinguishment (4) |  |  | -20 | -38 |
| Note discount (5) |  | 130 | 91 | 279 |
| Benefit from reversal of accrued payroll tax (6) |  |  |  | -522 |
| Net income (loss) - non-GAAP | -159 | 1 | -331 | -401 |
| Diluted EPS - GAAP | 0 | 0 | -0.01 | 0 |
| Change in fair value of convertible notes (3) |  |  | 0.01 |  |
| Diluted EPS - non-GAAP | 0 | 0 | 0 | 0 |
| Shares used to calculate diluted EPS - GAAP and non-GAAP | 205,086 | 184,264 | 198,943 | 184,264 |

### Income Statement (Three Months Ended June 30, (in thousands))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Net loss | -775 | -261 | -1,418 | -370 |
| Depreciation expense | 16 | 52 | 32 | 128 |
| Amortization expense | 5 | 6 | 12 | 12 |
| Interest expense, net | 1 | 130 | 94 | 281 |
| Income tax expense | 5 |  | 5 | 7 |
| EBITDA | -748 | -73 | -1,275 | 58 |
| Stock-based compensation (1) | 148 | 132 | 296 | 250 |
| Loss on debt conversions (2) | 104 |  | 249 |  |
| Change in fair value of convertible notes (3) | 364 |  | 471 |  |
| Gain on debt extinguishment (4) |  |  | -20 | -38 |
| Benefit from reversal of accrued payroll tax (5) |  |  |  | -522 |
| Adjusted EBITDA | -132 | 59 | -279 | -252 |

### Balance Sheet (June 30, 2026 — (in thousands, except per share data))

| | June 30, 2026 | December 31, 2025 |
|---|---:|---:|
| Current assets: | Cash | 266 | 278 |
| Current assets: | Accounts receivable, net | 348 | 402 |
| Current assets: | Inventory | 3,965 | 4,087 |
| Current assets: | Prepaid expenses and other | 300 | 366 |
| Current assets: | Total current assets | 4,879 | 5,133 |
| Current assets: | Property and equipment, net | 319 | 344 |
| Current assets: | Right of use assets | 215 | 347 |
| Current assets: | Intangibles, net | 62 | 76 |
| Current assets: | Goodwill | 999 | 1,015 |
| Current assets: | Other assets | 47 | 47 |
| Current assets: | Total assets | 6,521 | 6,962 |
| Current liabilities: | Accounts payable | 1,059 | 1,044 |
| Current liabilities: | Accrued expenses | 2,631 | 2,447 |
| Current liabilities: | Current portion of operating lease liability | 218 | 247 |
| Current liabilities: | Convertible notes, at fair value | 1,017 |  |
| Current liabilities: | Current portion of long-term debt, net | 18 | 1,262 |
| Current liabilities: | Total current liabilities | 4,943 | 5,000 |
| Current liabilities: | Operating lease liability |  | 100 |
| Current liabilities: | Debt, net |  | 387 |
| Current liabilities: | Deferred tax liability | 7 | 7 |
| Current liabilities: | Total liabilities | 4,950 | 5,494 |
| Stockholders' equity | Common stock, par value $0.0001; 790,000 shares authorized as of June 30, 2026 and December 31, 2025; 213,122 and 184,264 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 21 | 18 |
| Stockholders' equity | Additional paid-in capital | 90,881 | 89,330 |
| Stockholders' equity | Accumulated deficit | -89,357 | -87,939 |
| Stockholders' equity | Accumulated other comprehensive income | 26 | 59 |
| Stockholders' equity | Total stockholders' equity | 1,571 | 1,468 |
| Stockholders' equity | Total liabilities and stockholders' equity | 6,521 | 6,962 |

### Cash Flow (Six Months Ended June 30, — (in thousands))

| | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|
| OPERATING ACTIVITIES | Net loss | -1,418 | -370 |
| Adjustments to reconcile net loss to net cash flows provided by operating activities: | Depreciation and amortization | 45 | 140 |
| Adjustments to reconcile net loss to net cash flows provided by operating activities: | Stock-based compensation | 296 | 250 |
| Adjustments to reconcile net loss to net cash flows provided by operating activities: | Amortization of debt discount | 91 | 279 |
| Adjustments to reconcile net loss to net cash flows provided by operating activities: | Loss on debt conversion | 26 |  |
| Adjustments to reconcile net loss to net cash flows provided by operating activities: | Initial fair value of true-up convertible notes issued | 223 |  |
